DUSC public release documents by condition
Page last updated: 22 November 2024
- Acute allergic reaction with anaphylaxis, adrenaline autoinjectors, October 2020
- Acute coronary syndrome, ticagrelor, February 2016
- Age-related macular degeneration, aflibercept and ranibizumab June 2015 1
- Alzheimer disease, February 2016
- AMD, DMO and RVO, ranibizumab and aflibercept, May 2018
- Ankylosing spondylitis, bDMARDs, February 2016
- Ankylosing spondylitis, bDMARDS, June 2016
- Asthma, dupilumab, February 2024
- Asthma, uncontrolled severe allergic and eosinophilic asthma, October 2019
- Attention deficit hyperactivity disorder, Pharmaceutical Benefits Scheme (PBS) and Repatriation PBS (R/PBS) listed medicines, September 2023
- Attention Deficit Hyperactivity Disorder, Guanfacine, June 2021
- Attention Deficit Hyperactivity Disorder, May 2018
- Attention deficit hyperactivity disorder, June 2015
- Atypical haemolytic uremic syndrome (aHUS), eculizumab, October 2020
- Atypical haemolytic uraemic syndrome (aHUS), eculizumab, utilisation update, February 2019
- Atypical Haemolytic Uraemic Syndrome (aHUS), eculizumab, September 2017
- Benign prostatic hyperplasia, dutasteride and dutasteride with tamsulosin, June 2015
- Bone metastases, June 2014
- Breast cancer, everolimus, February 2017
- Breast cancer, medicines for HER2 positive metastatic breast cancer, February 2018
- Chronic lymphocytic leukaemia or small lymphocytic lymphoma, venetoclax, September 2023
- Chronic lymphocytic leaukaemia/ small lymphocytic lymphoma, ibrutinib, October 2020
- Chronic migraine, galcanezumab and fremanezumab, June 2024
- Chronic migraine - Botulinum toxin, June 2017
- Chronic myeloid leukaemia, tyrosine kinase inhibitors, October 2019
- Chronic myeloid leukaemia, tyrosine kinase inhibitors, February 2014
- Chronic plaque psoriasis, bDMARDs, June 2014
- Chronic spontaneous urticaria, omalizumab, June 2020
- Chronic spontaneous urticaria, omalizumab, June 2023
- Crohn's disease, bDMARDs, February 2015
- Crohn disease, June 2017
- Cystic fibrosis: dornase and mannitol, October 2014
- Cystic fibrosis, ivacaftor predicted versus actual analysis, February 2018
- Cystic fibrosis: tobramycin inhalation 24 month review, October 2014
- Deep vein thrombosis, pulmonary embolism and recurrent venous thromboembolism, novel oral anticoagulants, October 2014
- Diabetes, February 2017
- Dry eye syndrome, ocular lubricants, February 2021
- Epithelial ovarian, fallopian tube or primary peritoneal cancer, bevacizumab, 24 months review, September 2018
- Extensive-stage small cell lung cancer, atezolizumab, September 2022
- Gastrointestinal acid related disorders, Proton pump inhibitor (PPI} medicines, June 2022
- Gastrointestinal stromal tumour, imatinib, February 2017
- Glaucoma, June 2016
- Gout, febuxostat, September 2018
- Hepatic encephalopathy, rifaximin, September 2016
- Hepatitis B, February 2015
- Hepatitis C, direct acting antiviral medicines, September 2018
- Hereditary angioedema, icatibant, June 2015
- HIV, Bictegravir+emtricitabine+tenofovir alafenamide and dolutegravir+rilpivirine, October 2021
- HIV and PrEP, NPS analysis on HIV and PrEP medications using MedicineInsight and PBS data, October 2021
- Hypercholesterolaemia, evolocumab, February 2023
- Hypercholesterolaemia, evolocumab for heterozygous familial hypercholesterolaemia, June 2021
- Hyperphenylalaninaemia due to tetrahydrobiopterin (BH4) deficiency, sapropterin, June 2019
- Hypercholesterolaemia, ezetimibe with simvastatin, October 2014
- Hypercholesterolaemia, evolocumab for homozygous familial hypercholesterolaemia, October 2019
- Idiopathic pulmonary fibrosis, nintedanib and pirfenidone, February 2020
- Idiopathic thrombocytopenic purpura, romiplostim and eltrombopag, June 2015
- Iron deficiency anaemia, ferric carboxymaltose, February 2017
- Lymphoma, bendamustine, 24 month predicted versus actual analysis, February 2019
- Medicines for the treatment of locally advanced and metastatic breast cancer, Palbociclib, February 2022
- Melanoma, nivolumab, September 2022
- Melanoma, May 2018
- Metastatic colorectal cancer, February 2018
- Metastatic prostate cancer, oral medicines, June 2016
- Merkel cell carcinoma, Avelumab, February 2022
- Mesothelioma, nivolumab and ipilimumab, February 2024
- Multiple myeloma, September 2017
- Multiple myeloma, lenalidomide for newly diagnosed multiple myeloma, October 2019
- Multiple Sclerosis, alemtuzumab, February 2020
- Multiple Sclerosis, October 2015
- Myelodysplastic syndrome, lenalidomide, September 2017
- Myelofibrosis, ruxolitinib, 24 months review, September 2018
- Narcolepsy, armodafinil, June 2019
- Neuropathic pain, pregabalin, 12 month review, October 2014
- Neuropthic pain, pregabalin, 24 month review, October 2015
- Non-radiographic axial spondyloarthritis, Golimumab, October 2021
- Non-small cell lung cancer, medicines for treatment including durvalumab, September 2022
- Non-small cell lung cancer, alectinib, October 2020
- Non-small cell lung cancer, nivolumab, June 2020
- Non-small cell lung cancer, erlotinib and gefitinib, February 2017
- Non-valvular atrial fibrillation, novel oral anticoagulants, June 2016
- Osteoporosis, romosozumab, February 2024
- Osteoporosis, denosumab, October 2020
- Osteoporosis, September 2016
- Ovarian, fallopian tube and primary peritoneal cancer, olaparib, June 2023
- Chronic spontaneous urticaria, omalizumab, June 2020
- Pancreatic cancer, nab-paclitaxel, September 2017
- pNET, everolimus and sunitinib, September 2017
- Polycystic kidney disease, Tolvaptan, October 2021
- Preterm birth, progesterone, February 2024
- Prophlyaxis of fungal infections, posaconazole 24 month review, May 2018
- Psoriatic arthritis, bDMARDS, October 2015
- Pulmonary Arterial hypertension, February 2015
- Psoriatic arthritis, bDMARDs, February 2016
- Relapsing remitting multiple sclerosis, Cladribine, February 2022
- Relapsing-remitting multiple sclerosis, ocrelizumab, October 2020
- Renal cell carcinoma, pazopanib and sunitinib, June 2014
- Renal cell carcinoma, Nivolumab plus Ipilimumab, October 2021
- Renal cell carcinoma, nivolumab, June 2020
- Severe atopic dermatitis, dupilumab, September 2023
- Severe chronic plaque psoriasis, apremilast, September 2023
- Short Bowel Syndrome, Teduglutide, June 2022
- Spasticity and dystonia, botulinum toxin, May 2018
- Spinal muscular atrophy, nusinersen, February 2021
- Systemic fungal infections, antifungals, September 2016
- T-cell lymphoma, brentuximab vedotin, June 2024
- Tuberous sclerosis complex, everolimus, February 2017
- Type 2 diabetes mellitus, semaglutide, June 2024
- Type 2 diabetes, September 2022
- Type 2 diabetes, October 2012 and February 2013
- Type 2 diabetes, exenatide, October 2014
- Urothelial carcinoma, Pembrolizumab, October 2021
- Ulcerative colitis, June 2017
- Ulcerative colitis, 5-aminosalicylic acids, September 2017
- Unresectable melanoma, ipilimumab and dabrafenib, October 2015
Suggested citation:
[1]Department of Health. Age Related Macular Degeneration: utilisation analysis. Canberra:
Department of Health; 2015. Available from http://www.pbs.gov.au/info/industry/listing/participants/public-release-docs/aflibercept-ranibizumab-prd-2015-06
